Inspyr Therapeutics (NSPX) Inspyr Therapeutics is an integrated clinical-stage biopharmaceutical company that is focused on developing targeted cancer therapeutics for the treatment of cancerous tumors, including breast, prostate, bladder, kidney, and lung cancer along with the development of novel therapies to treat cancer, inflammation, and other serious diseases. Inspyr, like Gilead’s Remdesivir utilizes similar targeting of adenosine for a novel COVID-19 treatment. Inspyr merged with Lewis and Clark Pharmaceuticals several years ago and since then has developed a proprietary, industry-leading technology platform based on adenosine chemistry and biology and a broad pipeline of novel therapies. Their pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist.
While developing new A2A and A2B adenosine antagonists as well as dual A2A/A2B adenosine antagonist with improved drug like properties resulting in better bioavailability for the treatment of:
? Cancer ? Asthma ? Diabetes
Broad pipeline of novel therapies for oncology and inflammation.
Lewis and Clark's pipeline of novel proprietary therapies includes four lead programs: a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. These therapies are highly potent and selective, with important molecular properties that enable enhanced distribution in tissue and penetration of human skin. These therapies are in advanced preclinical development.
The dual A2A/A2B antagonist has both immune function modulation and anti-angiogenic properties and thus has potential as an immuno-oncology and anti-angiogenic agent to treat multiple types of solid and hematological malignancies.
The A2A agonists offers the potential to treat inflammatory and autoimmune diseases as arthritis, Crohn's disease, diabetic nephropathy, and psoriasis.
The A2B antagonist offers the potential to treat asthma, type 2 diabetes, atherosclerosis, and nonalcoholic fatty liver disease.
Inspyr's lead therapy, Mipsagargin, currently is in development for the treatment of solid tumors.
For liver cancer, Mipsagargin in combination with Nexavar(R) is being evaluated in a preclinical study in liver tumor models that express different levels of PSMA, the target of Mipsagargin. Inspyr is finalizing the design of a clinical study to examine the potential benefits of Mipsagargin in combination with Nexavar(R) in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.
For gastric cancer, Inspyr has initiated a preclinical study in gastric cancer tumor models that express different levels of PSMA. In this initial study, Mipsagargin will be evaluated first in combination with paclitaxel and in a subsequent study will be evaluated in combination with DC101 (Cyramza(R) surrogate antibody).
Utilizing Lewis and Clark's wet laboratory facilities, Inspyr has the potential to internally develop additional pro-drugs targeting PSMA with different toxic payloads.
A potential cancer killer not in the commercial markets yet.
In addition to their cutting-edge therapies, Inspyr's board of directors have extensive experience along with strong ties to Pfizer (PFE), Glaxo Smith Kline (GSK), Exelixis (EXEL), and Astellas Pharma (ALPMF). In previous years, Inspyr Therapeutics (formerly GenSpera) has raised tens of millions in equity funding, received millions in grants, and on 1/21/20, leading hedge fund Shabby Management LLC and their associated funds announced an ownership stake of nearly 40% in NSPX. Then on 3/6/20, Inspyr filed an 8-K with the SEC in that the company sold an aggregate of $250,000 of senior convertible debentures (“Debentures”) for cash to existing accredited institutional investors of the Company (the “Offering”) with an original set conversion price was $0.33. Looking at the recent surge in volume and the share price of NSPX over the past few days, it's reason to think there is some serious correlation connecting the funds behind Inspyr, recent disclosures, their extensive patent portfolio, and the proprietary technology and drugs they have that can be quickly repurposed to treat and possibly cure this new novel coronavirus COVID-19 and put an end to this global pandemic.[/I]
News 
Market Data 
Discover 
